Bristol Myers Squibb (BMY) stock
Health Care · Pharmaceuticals
Bristol Myers Squibb (BMY) is a Pharmaceuticals company in the Health Care sector, headquartered in New York City, New York. As of October 23, 2026, BMY closed at $61.48, a market capitalization of $125.59 billion, the 97th largest company in the S&P 500. Over the last twelve months it generated $49.19 billion in revenue (+6% year over year) and $11.44 billion in free cash flow. The stock trades at 13.5x trailing earnings and 9.3x forward earnings.
- 1-year total return: +46.5% (dividends reinvested)
- 5-year return: +5.6% a year
- 52-week range: $42.52 – $68.64
- Gross margin 71.7%, operating margin 34.4%
- Dividend yield: 4.10%, 18 straight years of increases
- FI Handbook report card: B across 10 metrics
- 14th largest of 60 Health Care stocks in the S&P 500
BMY price chart
1Y price change: +40.3% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| BMY | +1.6% | +19.1% | +46.5% | +8.1% | +5.6% | +5.8% | +10.4% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1972.
BMY key statistics
- Market cap
- $125.6B
- #97 in S&P 500
- P/E (TTM)
- 13.5x
- Forward P/E
- 9.3x
- EPS (TTM)
- $4.54
- Revenue (TTM)
- $49.2B
- +6%
- Free cash flow
- $11.4B
- Gross margin
- 71.7%
- Operating margin
- 34.4%
- Return on equity
- 46.6%
- Dividend yield
- 4.10%
- 52-week range
- $42.52 – $68.64
- Beta
- 0.18
- Price / sales
- 2.6x
- EV / EBITDA
- 8.4x
- Debt / equity
- 2.02x
- Employees
- 32,500
BMY report card
BTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth5.7%C
- Gross margin71.7%A
- Operating margin34.4%A
- FCF margin23.3%B
- Return on equity46.6%A
- Net debt / EBITDA1.8xC
- Forward P/E9.3xA
- PEG ratio2.4xD
- Shareholder yield4.1%B
- Share count change / yr-2.0%A
Bristol-Myers Squibb financials
Revenue went from $19.4B in fiscal 2016 to $48.2B in fiscal 2025, growing 10.6% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Gross profit | $14.5B | $14.7B | $16.1B | $18.1B | $30.7B | $36.4B | $36.0B | $34.3B | $34.3B | $34.3B |
| Net income | $4.5B | $1.0B | $4.9B | $3.4B | -$9.0B | $7.0B | $6.3B | $8.0B | -$8.9B | $7.1B |
| EPS (diluted) | $2.65 | $0.61 | $3.01 | $2.01 | $-3.99 | $3.12 | $2.95 | $3.86 | $-4.41 | $3.46 |
| Free cash flow | $1.8B | $4.2B | $6.1B | $7.4B | $13.3B | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B |
| Buybacks | $231.0M | $2.5B | $320.0M | $7.3B | $1.5B | $6.3B | $8.0B | $5.2B | $0 | $0 |
| Dividends paid | $2.5B | $2.6B | $2.6B | $2.7B | $4.1B | $4.4B | $4.6B | $4.7B | $4.9B | $5.0B |
| Diluted shares | 1.7B | 1.7B | 1.6B | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 2.0B | 2.0B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into BMY?
A reverse DCF asks what growth the current price requires. With an enterprise value of $159.6B and $11.4B of trailing free cash flow, Bristol-Myers Squibb needs to grow free cash flow about 1.7% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew -0.7% a year over the last five years.
P/E ratio history
Current 17.8x vs. median 21.0x (10th–90th percentile 9.3x–61.0x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
BMY dividend
- Dividend yield
- 4.10%
- Annual dividend
- $2.52
- Years of increases
- 18
- 5-yr dividend growth
- 1.6%
- per year
- Payout ratio
- 55%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
BMY analyst price targets
24 analysts' average 12-month target is $65.42 (+6% vs. $61.48). Targets range from $41.00 to $82.00. 36% rate it a buy.
BMY earnings
Next report: October 29, 2026. Bristol-Myers Squibb has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $13.0B (+6% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 30, 2026 | $1.60 | $2.04 | +27.7% |
| Apr 30, 2026 | $1.42 | $1.58 | +11.2% |
| Feb 5, 2026 | $1.20 | $1.26 | +4.6% |
| Oct 30, 2025 | $1.52 | $1.63 | +7.5% |
| Jul 31, 2025 | $1.10 | $1.46 | +32.6% |
| Apr 24, 2025 | $1.50 | $1.80 | +19.9% |
| Feb 6, 2025 | $1.47 | $1.67 | +13.8% |
| Oct 31, 2024 | $1.50 | $1.80 | +20.0% |
Stocks like BMY
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 PFE Pfizer | -1.28% | +30% | $171.2B | 39.5x | Compare |
 ZTS Zoetis | -1.18% | -44% | $33.5B | 13.3x | Compare |
 VTRS Viatris | -2.60% | +81% | $20.7B | — | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
BMY news
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy · Oct 25, 2026
- The Call Bristol-Myers Squibb Bulls Got Right · Oct 25, 2026
- Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know · Oct 23, 2026
- BMY Stock Falls 2% After Patient Death In Early Multiple Sclerosis CAR T Trial · Oct 23, 2026
- Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data · Oct 23, 2026
BMY stock FAQ
What is BMY's market cap?
Bristol Myers Squibb's market capitalization is $125.59 billion as of October 23, 2026, ranking 97th in the S&P 500.
What is BMY's P/E ratio?
BMY trades at a trailing price-to-earnings ratio of 13.5x and a forward P/E of 9.3x. Its median P/E over the period we track is 21.0x.
Does BMY pay a dividend?
Yes. Bristol Myers Squibb pays $2.52 per share a year, a 4.10% yield. It has raised its dividend 18 years in a row. Dividends grew 1.6% a year over the last five years.
How much has BMY stock returned?
Including reinvested dividends, BMY returned +46.5% over one year, +5.6% a year over five years, +5.8% a year over ten years through October 23, 2026.
Is BMY stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Bristol Myers Squibb must grow free cash flow about 2% a year for the next decade. Its free cash flow fell 1% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the BMY price target?
24 analysts cover BMY with an average 12-month price target of $65.42, +6% from the current price. 36% of them rate it a buy.
When does BMY report earnings?
Bristol Myers Squibb is expected to report earnings on October 29, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Bristol Myers Squibb have?
Bristol Myers Squibb has about 32,500 full-time employees, or $1.5 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology